Atherosclerosis Mechanisms: Angiotensin II production and action
动脉粥样硬化机制:血管紧张素 II 的产生和作用
基本信息
- 批准号:10132375
- 负责人:
- 金额:$ 48.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-05-01 至 2023-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAmino Acid SequenceAndrogensAngiotensin IIAngiotensin Type 1a ReceptorAngiotensinogenArterial Fatty StreakAtherosclerosisBindingBreedingCell Culture SystemCleaved cellColorConserved SequenceDataDevelopmentElementsEndocrine systemEndothelial CellsEnzymesFibroblastsGenesHepatocyteHumanIn VitroInfusion proceduresKidneyLDL-Receptor Related Protein 2LesionLeukocytesLiteratureLocationLow Density Lipoprotein ReceptorLoxP-flanked alleleMediatingMethodsMusMutagenesisNephronsPathway interactionsPeptidyl-Dipeptidase APharmacologyPlayProductionProteinsReninRenin-Angiotensin SystemReproducibilityRoleSiteSmooth Muscle MyocytesSourceSurface Plasmon ResonanceSystemTechniquesTestingTherapeuticTransgenesTransgenic MiceViralbasecell typeenzyme deficiencyexperimental studyhypercholesterolemiainsightmembermouse modelmutantnovel therapeutic interventionpreventpromoterprotein structurereceptorurinary
项目摘要
Abstract
The renin angiotensin system (RAS) plays a critical role in the development of
atherosclerosis. Mechanisms by which the RAS contributes to atherosclerosis have been
focusing on effects of angiotensin II (AngII) production and its action through AT1a receptors
within atherosclerotic lesions. On the basis of our preliminary data, we challenge this concept
and propose a new hypothesis: Renal AngII production through a megalin-mediated
pathway in proximal convoluted tubules (PCTs) promotes atherosclerosis via its local
stimulation of AT1a receptors. Angiotensinogen (AGT), the substrate of the RAS, derived
from hepatocytes is filtered through glomeruli and retained by megalin, a member of LDL
receptor superfamily, in PCTs. Our protein sequence and structure analyses identified two
conserved sequences that may associate with its binding to megalin. Aim 1 will define how
hepatocyte-derived AGT regulates renal AngII production and contributes to atherosclerosis.
We will use site-mutagenesis, surface plasmon resonance, and cell culture system to determine
how AGT and megalin interact in vitro. Subsequently, we will use an adeno-associated viral
(AAV) system to manipulate conserved sequences of AGT in hepatocyte-specific AGT deficient
mice to determine whether conserved sequences of AGT influence renal AngII production and
atherosclerosis. Effects of megalin on renal AngII production and atherosclerosis will be
determined using PCT-specific megalin deficient mice. Since AGT is cleaved by two critical
enzymes, renin and angiotensin-converting enzyme (ACE), to produce AngII, Aim 2 will first
determine whether renin or ACE derived from PCTs contributes to renal AngII production and
atherosclerosis using PCT-specific renin and ACE deficient mice, respectively. Studies
proposed in Aim 1 for AGT and megalin interaction and Aim 2 for the two enzymes (renin and
ACE) do not provide direct evidence whether AngII produced in PCTs contributes to
atherosclerosis. To answer this question, we will use a transgenic mouse model that has
restricted production of AngII in PCTs. AngII promotes atherosclerosis through AT1a receptor-
mediated mechanism. Therefore, subsequent experiments will determine whether PCTs are the
location for AT1a receptors to promote atherosclerosis. Completion of proposed studies will
provide evidence whether renal PCTs are the major source for each classic RAS component to
promote atherosclerosis. Demonstration of this new concept may change our understanding of
the AngII/AT1a receptor-mediated mechanisms of atherosclerosis, which may also provide
insights into developing new therapeutic strategies.
抽象的
肾素血管紧张素系统(RAS)在发展中起着至关重要的作用
动脉粥样硬化。 RAS导致动脉粥样硬化的机制已
重点关注血管紧张素II(ANGII)产生的作用及其通过AT1A受体的作用
在动脉粥样硬化病变内。根据我们的初步数据,我们挑战这个概念
并提出了一个新的假设:通过Megalin介导的肾脏Angii产生
近端复杂小管(PCT)的途径通过其局部促进动脉粥样硬化
刺激AT1A受体。血管紧张素原(AGT),Ras的底物,得出
肝细胞通过肾小球过滤,并由LDL成员Megalin保留
受体超家族,在PCT中。我们的蛋白质序列和结构分析确定了两个
可能与其与梅加林结合的保守序列。 AIM 1将定义如何
肝细胞衍生的AGT调节肾血管生产,并导致动脉粥样硬化。
我们将使用位点 - 毒素,表面等离子体共振和细胞培养系统来确定
Agt和Megalin如何在体外相互作用。随后,我们将使用与腺相关的病毒
(AAV)在肝细胞特异性AGT中操纵AGT的保守序列的系统
小鼠确定AGT的保守序列是否影响肾ANGII产生和
动脉粥样硬化。 Megalin对肾血管肌产生和动脉粥样硬化的影响将是
使用PCT特异性巨蛋白缺乏小鼠确定。由于AGT被两个关键
酶,肾素和血管紧张素转换酶(ACE)为产生Angii,AIM 2将首先
确定源自PCT的肾素或ACE是否有助于肾ANGII产生和
分别使用PCT特异性肾素和ACE缺乏小鼠的动脉粥样硬化。研究
在AIM 1中提出了针对AGT和Megalin相互作用的AIM 1,并将AIM 2用于两种酶(Renin和Renin和
ACE)不提供直接证据
动脉粥样硬化。要回答这个问题,我们将使用具有的转基因鼠标模型
PCT中ANGII的产生限制。 AngII通过AT1A受体促进动脉粥样硬化
中介机制。因此,随后的实验将确定PCT是否为
AT1A受体促进动脉粥样硬化的位置。拟议研究的完成将
提供肾脏PCT是否是每个经典RAS组件的主要来源
促进动脉粥样硬化。这个新概念的演示可能会改变我们对
Angii/At1a受体介导的动脉粥样硬化机制,这也可能提供
对制定新的治疗策略的见解。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A mini-review on quantification of atherosclerosis in hypercholesterolemic mice.
- DOI:10.36922/gtm.v1i1.76
- 发表时间:2022-01-01
- 期刊:
- 影响因子:0
- 作者:Chen, Hui;Howatt, Deborah A;Lu, Hong S
- 通讯作者:Lu, Hong S
Links lipoproteins to chronic kidney disease and atherosclerosis.
- DOI:10.1097/mol.0000000000000625
- 发表时间:2019-10
- 期刊:
- 影响因子:4.4
- 作者:Hong S. Lu;M. Kukida;A. Daugherty
- 通讯作者:Hong S. Lu;M. Kukida;A. Daugherty
Editorial: Cardiovascular Fibrosis and Related Diseases: Basic and Clinical Research Advances.
- DOI:10.3389/fcvm.2022.879780
- 发表时间:2022
- 期刊:
- 影响因子:3.6
- 作者:Bei Y;Lu HS;Zhong J
- 通讯作者:Zhong J
Manipulation of components of the renin angiotensin system in renal proximal tubules fails to alter atherosclerosis in hypercholesterolemic mice.
- DOI:10.3389/fcvm.2023.1250234
- 发表时间:2023
- 期刊:
- 影响因子:3.6
- 作者:Kukida, Masayoshi;Amioka, Naofumi;Ye, Dien;Chen, Hui;Moorleghen, Jessica J.;Liang, Ching-Ling;Howatt, Deborah A.;Katsumata, Yuriko;Yanagita, Motoko;Sawada, Hisashi;Daugherty, Alan;Lu, Hong S.
- 通讯作者:Lu, Hong S.
Reporting Sex and Sex Differences in Preclinical Studies.
- DOI:10.1161/atvbaha.118.311717
- 发表时间:2018-10
- 期刊:
- 影响因子:0
- 作者:Lu HS;Schmidt AM;Hegele RA;Mackman N;Rader DJ;Weber C;Daugherty A
- 通讯作者:Daugherty A
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alan Daugherty其他文献
Alan Daugherty的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alan Daugherty', 18)}}的其他基金
Acquisition of Shared Thermoneutral Rodent Housing Resources
获取共享的热中性啮齿动物住房资源
- 批准号:
10734172 - 财政年份:2023
- 资助金额:
$ 48.69万 - 项目类别:
Atherosclerosis Mechanisms: Angiotensin II production and action
动脉粥样硬化机制:血管紧张素 II 的产生和作用
- 批准号:
9903447 - 财政年份:2018
- 资助金额:
$ 48.69万 - 项目类别:
Adventitial-medial interactions in thoracic aortic diseases
胸主动脉疾病中外膜-内侧相互作用
- 批准号:
9160051 - 财政年份:2016
- 资助金额:
$ 48.69万 - 项目类别:
相似国自然基金
基于祖先序列重构的D-氨基酸解氨酶的新酶设计及分子进化
- 批准号:32271536
- 批准年份:2022
- 资助金额:54.00 万元
- 项目类别:面上项目
模板化共晶聚合合成高分子量序列聚氨基酸
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
模板化共晶聚合合成高分子量序列聚氨基酸
- 批准号:22201105
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
基于祖先序列重构的D-氨基酸解氨酶的新酶设计及分子进化
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
C-末端40个氨基酸插入序列促进细菌脂肪酸代谢调控因子FadR转录效率的机制研究
- 批准号:82003257
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
相似海外基金
Gut bacterial metabolism of the side-chain of corticosteroids
皮质类固醇侧链的肠道细菌代谢
- 批准号:
10703384 - 财政年份:2022
- 资助金额:
$ 48.69万 - 项目类别:
Atherosclerosis Mechanisms: Angiotensin II production and action
动脉粥样硬化机制:血管紧张素 II 的产生和作用
- 批准号:
9903447 - 财政年份:2018
- 资助金额:
$ 48.69万 - 项目类别:
Ack1: Activation and Consequences in Prostate Cancer
Ack1:前列腺癌中的激活和后果
- 批准号:
8270330 - 财政年份:2011
- 资助金额:
$ 48.69万 - 项目类别:
Ack1: Activation and Consequences in Prostate Cancer
Ack1:前列腺癌中的激活和后果
- 批准号:
8193120 - 财政年份:2011
- 资助金额:
$ 48.69万 - 项目类别:
Role of Rho GDP dissociation inhibitors in androgen signaling in prostate cancer
Rho GDP 解离抑制剂在前列腺癌雄激素信号传导中的作用
- 批准号:
7931327 - 财政年份:2010
- 资助金额:
$ 48.69万 - 项目类别: